Síndromes Linfoproliferativos Post Transplante

10 Fernandez MC, Bes D, De Davila M, Lopez S, Cambaceres C, Dip M, Imventarza O: Posttransplant
lymphoproliferative disorder after pediatric liver transplantation: characteristics and
outcome. Pediatr Transplant 2009;13:307-310.
11 Gao SZ, Chaparro SV, Perlroth M, Montoya JG, Miller JL, DiMiceli S, Hastie T, Oyer PE, Schroeder
J: Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients:
30-year experience at Stanford University. J Heart Lung Transplant 2003;22:505-514.
12 Styczynski J, Einsele H, Gil L, Ljungman P: Outcome of treatment of Epstein-Barr virus-related
post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a
comprehensive review of reported cases. Transpl Infect Dis 2009;11:383-392.
13 Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S: Prior immunosuppressive therapy with
antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following
allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009;43:813-816.
14 Faye A, Vilmer E: Post-transplant lymphoproliferative disorder in children: incidence,
prognosis, and treatment options. Paediatr Drugs 2005;7:55-65.
15 Shpilberg O, Wilson J, Whiteside TL, Herberman RB: Pre-transplant immunological profile and
risk factor analysis of post-transplant lymphoproliferative disease development: the results of a
nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk
Lymphoma 1999;36:109-121.
16 Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH: Mycophenolate, tacrolimus and
post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal
Transplant Cooperative Study. Pediatr Transplant 2002;6:396-399.
17 Jain A, Mazariegos G, Kashyap R, Green M, Gronsky C, Starzl TE, Fung J, Reyes J: Comparative
long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.
Transplantation 2000;70:617-625.
18 Cacciarelli TV, Reyes J, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Green M: Primary tacrolimus
(FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in
pediatric liver transplant recipients. Pediatr Transplant 2001;5:359-364.
19 Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C,
Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F: Diagnosis and treatment of posttransplantation
lymphoproliferative disorder in pediatric heart transplant patients. Pediatr
Transplant 2008.
20 Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P: Longitudinal analysis of Epstein-
Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by
real-time polymerase chain reaction. Transplantation 2002;74:656-664.
21 Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid
organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin
Oncol 2009;27:3354-3362.
22 Wu JF, Ho MC, Ni YH, Chen HL, Lu CY, Hsu HY, Lee PH, Chang MH: Timing of Epstein-Barr virus
acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Transplantation 2009;87:758-762.
Page 6 of 30